Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule With a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Volunteers Aged 18 to 59 Years

NCT00895544 is registered in ClinicalTrials.gov with Alachua Government Services, Inc. as lead sponsor.

NCT NCT00895544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00895544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule With a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Volunteers Aged 18 to 59 Years
Lead sponsor
Alachua Government Services, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2009
Completion date
June 30, 2011
Enrollment
231 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

avian influenza, influenza